|Day's Range||77.7200 - 78.3500|
|52 Week Range||64.1800 - 86.7200|
|PE Ratio (TTM)||37.74|
|Dividend & Yield||2.08 (2.66%)|
|1y Target Est||N/A|
Merck (MRK) got another approval for Keytruda while Aerie shot up on positive data.
In 1Q17, Amgen’s (AMGN) Nplate generated revenues of ~$154 million, which reflected a year-over-year growth rate of 9%.
Radius Health, Inc. (RDUS) announced positive data from the ACTIVExtend study on Tymlos demonstrating significant reduction (84%) in the incidence of new vertebral fractures compared to placebo when dosed daily for 43 months.